Scientists collaborating in a research laboratory

About the Society

Uniting the Global KLF/Sp Research Community

Born from nearly two decades of informal scientific exchange, the International Society for KLF Research is the formal home for investigators advancing the biology of Krüppel-like Factors worldwide.

Steering Committee

2025–2027

Konstantinos Drosatos

President

University of Cincinnati, USA

Jonathan Katz

Vice-President

University of Pennsylvania, USA

Laura Zelarayan

General Secretary

Justus-Liebig-Universität Giessen, Germany

Gwen Lomberk

Treasurer

Mayo Clinic Arizona, USA

Kate Quinlan

Councilor

UNSW Sydney, Australia

Ceshi Chen

Councilor

Kunming Medical University, China

Ichiro Manabe

Councilor

Chiba University, Japan

Advisory Board

Ryozo Nagai (Chair)

Chief Medical Officer of the Imperial Household of Japan

Mukesh Jain

Brown University, USA

Jim Bieker

Mount Sinai School of Medicine, USA

Raul Urrutia

Mayo Clinic Arizona, USA

Merlin Crossley

UNSW Sydney, Australia

Andrew Perkins

Monash University, Australia

Sarah Millar

Mount Sinai School of Medicine, USA

Background

Our History

The International Society for KLF Research grew out of a scientific community that had been meeting for nearly two decades before it took formal shape. In 2007, Ryozo Nagai — then Professor and Chairman of Cardiovascular Medicine at the University of Tokyo — proposed, in conversation with Scott Friedman of Mount Sinai and Masato Kasuga of Kobe University, that investigators working on the Krüppel-like factors should have a forum of their own, since the field had grown substantially without ever gathering in one room.

The 1st International Symposium on the Biology of the Krüppel-like Factors convened at the University of Tokyo on March 6–7, 2008. Subsequent meetings were held in the United States (2010, 2012, 2014, 2016), Japan (2018), and Greece (2024). In 2026 the community formalized itself: the Society was incorporated in Pennsylvania and recognized as a tax-exempt organization under section 501(c)(3) of the U.S. Internal Revenue Code, inaugurated at the KLF/SP meeting in Gießen, Germany, with Professor Nagai as Honorary President.

Key Milestones

2007
Ryozo Nagai proposes a dedicated KLF research forum
2008
1st International Symposium on KLF Biology, University of Tokyo
2010–2016
Four successive meetings held in the United States
2018
Meeting returns to Japan
2024
International meeting held in Greece
2026
Society formally incorporated in Pennsylvania; inaugurated during the KLF conference in Gießen, Germany

Molecular Biology

The KLFs

KLF/SP proteins constitute a single family of zinc finger-containing transcription factors that exhibit homology to the Drosophila gap gene product, Krüppel. There are at least 18 KLFs and 9 Sp proteins, with a multitude of important functions including regulation of proliferation, differentiation, inflammation/immunity, metabolism, and carcinogenesis. The family’s name originates with its founding member. Erythroid Krüppel-like factor (EKLF) was the first of these proteins to be identified, and the term “Krüppel-like factor” was coined by a comprehensive study performed by the group of James J. Bieker (1993). That first report directly influenced the isolation of many of the KLFs that followed, and EKLF has since been regarded as the founding member of the family — the reason the HUGO Gene Nomenclature Committee designated it KLF1. EKLF/KLF1 is now recognized as a master regulator of all aspects of erythropoiesis.

Dysregulation of KLF/SP-mediated pathways contributes to pathological states such as obesity, cancer, and inflammatory conditions. Recent studies indicate that many of these transcription factors have the ability to reprogram somatic cells to inducible pluripotent stem (iPS) cells, and to maintain the pluripotent state of embryonic stem cells — with several members able to substitute for one another in establishing and/or maintaining pluripotency. KLF4 has been recognized as one of the four factors whose forced expression converts human somatic cells into induced pluripotent stem cells. This finding overturned the view of differentiation as irreversible and brought Shinya Yamanaka a share of the 2012 Nobel Prize in Physiology or Medicine.

Molecular insights derived from zinc finger–DNA interactions, most thoroughly validated from work on Sp/KLF proteins, have given rise to a rapidly growing area of research: gene-editing by artificial KLF-like zinc finger proteins that allow for in vivo gene mutation, mutation repair, deletions, insertions, and other forms of engineering for both research and medical practice.

Proliferation & Differentiation

KLF/SP factors are master regulators of cell cycle progression and lineage commitment across virtually every tissue type.

Stem Cells & Reprogramming

KLF4 is a core Yamanaka reprogramming factor; multiple KLFs govern pluripotency and the maintenance of embryonic stem cell identity.

Inflammation & Immunity

KLF2 and KLF4 direct lymphocyte trafficking and macrophage polarization in both innate and adaptive immune responses.

Metabolism

KLF15 and KLF11 control metabolic gene programs in the liver, adipose tissue, and skeletal muscle, with links to obesity and diabetes.

Cancer

Sp1 and multiple KLFs are dysregulated in cancer, making the family an attractive set of therapeutic targets in oncology.

Gene Editing

Artificial KLF-like zinc finger proteins enable in vivo gene mutation, repair, deletion, and insertion — a transformational tool for research and medicine.

Become a Member

Join hundreds of researchers worldwide who are advancing the science of KLF and Sp transcription factors.